Mitigation of Respirable Aerosol Particles from Speech and Language Therapy Exercises.

Filters Masks Respirable aerosols SARS-CoV-2 Speech language pathology Voice therapy

Journal

Journal of voice : official journal of the Voice Foundation
ISSN: 1873-4588
Titre abrégé: J Voice
Pays: United States
ID NLM: 8712262

Informations de publication

Date de publication:
27 May 2023
Historique:
received: 16 03 2023
accepted: 05 04 2023
medline: 30 5 2023
pubmed: 30 5 2023
entrez: 29 5 2023
Statut: aheadofprint

Résumé

Phonation and speech are known sources of respirable aerosol in humans. Voice assessment and treatment manipulate all the subsystems of voice production, and previous work (Saccente-Kennedy et al., 2022) has demonstrated such activities can generate >10 times more aerosol than conversational speech and 30 times more aerosol than breathing. Aspects of voice therapy may therefore be considered aerosol generating procedures and pose a greater risk of potential airborne pathogen (eg, SARS-CoV-2) transmission than typical speech. Effective mitigation measures may be required to ensure safe service delivery for therapist and patient. To assess the effectiveness of mitigation measures in reducing detectable respirable aerosol produced by voice assessment/therapy. We recruited 15 healthy participants (8 cis-males, 7 cis-females), 9 of whom were voice-specialist speech-language pathologists. Optical Particle Sizers (OPS) (Model 3330, TSI) were used to measure the number concentration of respirable aerosol particles (0.3 µm-10 µm) generated during a selection of voice assessment/therapy tasks, both with and without mitigation measures in place. Measurements were performed in a laminar flow operating theatre, with near-zero background aerosol concentration, allowing us to quantify the number concentration of respiratory aerosol particles produced. Mitigation measures included the wearing of Type IIR fluid resistant surgical masks, wrapping the same masks around the end of straws, and the use of heat and moisture exchange microbiological filters (HMEFs) for a water resistance therapy (WRT) task. All unmitigated therapy tasks produced more aerosol than unmasked breathing or speaking. Mitigation strategies reduced detectable aerosol from all tasks to a level significantly below, or no different to, that of unmasked breathing. Pooled filtration efficiencies determined that Type IIR surgical masks reduced detectable aerosol by 90%. Surgical masks wrapped around straws reduced detectable aerosol by 96%. HMEF filters were 100% effective in mitigating the aerosol from WRT, the exercise that generated more aerosol than any other task in the unmitigated condition. Voice therapy and assessment causes the release of significant quantities of respirable aerosol. However, simple mitigation strategies can reduce emitted aerosol concentrations to levels comparable to unmasked breathing.

Identifiants

pubmed: 37248120
pii: S0892-1997(23)00124-8
doi: 10.1016/j.jvoice.2023.04.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Brian Saccente-Kennedy (B)

Department of Speech and Language Therapy (ENT), Royal National Ear, Nose and Throat and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Alicja Szczepanska (A)

School of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.

Joshua Harrison (J)

School of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.

Justice Archer (J)

School of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.

Natalie A Watson (NA)

Department of Ear, Nose and Throat Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Christopher M Orton (CM)

Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom; Department of Respiratory Medicine, Chelsea and Westminster Hospital, London, United Kingdom; National Heart and Lung Institute, Guy Scadding Building, Imperial College London, London, United Kingdom.

Declan Costello (D)

Ear, Nose and Throat Department, Wexham Park Hospital, United Kingdom.

James D Calder (JD)

Department of Bioengineering, Imperial College London, United Kingdom; Fortius Clinic, Fitzhardinge St, London, United Kingdom.

Pallav L Shah (PL)

Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom; Department of Respiratory Medicine, Chelsea and Westminster Hospital, London, United Kingdom; National Heart and Lung Institute, Guy Scadding Building, Imperial College London, London, United Kingdom.

Jonathan P Reid (JP)

School of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.

Bryan R Bzdek (BR)

School of Chemistry, University of Bristol, Cantock's Close, Bristol, United Kingdom.

Ruth Epstein (R)

Department of Speech and Language Therapy (ENT), Royal National Ear, Nose and Throat and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: ruth.epstein@nhs.net.

Classifications MeSH